Galectin Therapeutics INC 8-K filings

Galectin Therapeutics reported Q2 2026 financial results, highlighting an agreement with the FDA for its Phase 3 belapectin trial in MASH cirrhosis and a substantial debt conversion into equity.

Galectin Therapeutics Inc. announced the conversion of approximately $105.8 million in debt, including principal and accrued interest, into common stock by Chairman Richard E. Uihlein, significantly strengthening its balance sheet.

Galectin Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its belapectin program for MASH cirrhosis and providing a business update.

Galectin Therapeutics announced its 2025 financial results, highlighted progress in its belapectin development program for MASH cirrhosis, and extended its cash runway through April 2027.

Galectin Therapeutics Inc. announced the appointment of internationally recognized neurosurgeon-scientist Dr. Henry Brem as an independent director to its Board of Directors, effective March 12, 2026.

Galectin Therapeutics' Board of Directors approved cash retention bonuses for its Chief Medical Officer and Chief Financial Officer, totaling $450,000.

Galectin Therapeutics Inc. announced the resignation of Marc Rubin from its Board of Directors, effective January 10, 2026.

Galectin Therapeutics announced a new $10 million line of credit from its chairman and positive FDA feedback on its belapectin development for MASH cirrhosis.

Galectin Therapeutics Inc. announced that its stockholders approved all nominated directors, executive compensation, and ratified Cherry Bekaert LLP as its independent auditor at the 2025 Annual Meeting.

Galectin Therapeutics presented compelling biomarker and clinical data from its NAVIGATE trial, reinforcing belapectin's potential for MASH cirrhosis.

Galectin Therapeutics announced its Q3 2025 financial results and provided a business update, highlighting positive 18-month biomarker data for belapectin in MASH cirrhosis and ongoing FDA dialogue.

Galectin Therapeutics announced positive biomarker and clinical outcome analyses from its NAVIGATE trial for belapectin in MASH cirrhosis with portal hypertension at the AASLD 2025 Annual Meeting.

Galectin Therapeutics Inc. announced promising 18-month results from its NAVIGATE trial for Belapectin in MASH cirrhosis, showing a statistically significant reduction in the composite primary endpoint and new varices in the per-protocol population.

Galectin Therapeutics reported Q2 2025 financial results and provided an update on its NAVIGATE trial, highlighting sustained efficacy of belapectin in MASH cirrhosis.

Galectin Therapeutics Inc. announced a new $10 million line of credit from Richard E. Uihlein, extending existing debt maturities and implementing new employee retention bonuses to fund operations through June 2026.

Galectin Therapeutics Inc. announced positive 18-month results from its NAVIGATE Phase 2b trial, demonstrating that Belapectin significantly reduced the incidence of new esophageal varices in patients with MASH cirrhosis and portal hypertension.

Galectin Therapeutics announced encouraging data from its belapectin program for MASH cirrhosis and portal hypertension, along with its financial results for the first quarter of 2025.

Galectin Therapeutics' NAVIGATE trial shows belapectin 2 mg/kg significantly reduces new varices in MASH cirrhosis patients in the per-protocol population.

Galectin Therapeutics reported its 2024 financial results, highlighting progress with its belapectin program and securing additional funding.

Galectin Therapeutics released an updated corporate presentation highlighting clinical trial results for Belapectin in MASH cirrhosis and cancer immunotherapy, with a focus on the NAVIGATE trial and its findings on varices prevention.

Galectin Therapeutics announces a significant reduction in new varices with belapectin in U.S. patients from the NAVIGATE trial, indicating potential for treating MASH cirrhosis.

Galectin Therapeutics successfully elected all nominated directors and ratified the selection of Cherry Bekaert LLP as their independent auditor at the 2024 Annual Meeting of Stockholders.

Galectin Therapeutics reports favorable clinical effects of belapectin in patients with cirrhosis caused by MASH, demonstrating a significant reduction in new varices in the NAVIGATE trial.

Galectin Therapeutics announced results from its NAVIGATE trial of belapectin for MASH cirrhosis, showing a meaningful reduction in the development of new esophageal varices at the 2 mg dose, alongside ongoing analyses and plans to explore partnership opportunities.

Galectin Therapeutics' NAVIGATE trial showed a statistically significant reduction in esophageal varices in a pre-specified patient group treated with belapectin, but failed to reach statistical significance in the overall study population.

Galectin Therapeutics is advancing its lead drug candidate, Belapectin, for MASH cirrhosis and cancer, with topline results from the NAVIGATE trial expected in December 2024.

Galectin Therapeutics announced its Q3 2024 financial results and provided a business update, highlighting the progress of its NAVIGATE trial for belapectin.

Galectin Therapeutics has released an updated corporate presentation, emphasizing the potential of its lead drug, belapectin, in treating MASH cirrhosis and cancer, with an interim readout of a Phase 2b/3 trial expected in Q4 2024.

Galectin Therapeutics announced its Q2 2024 financial results and provided a business update, highlighting the progress of its NAVIGATE trial and upcoming interim analysis.

Galectin Therapeutics has appointed Dr. Khurram Jamil as Chief Medical Officer, effective immediately, succeeding Dr. Pol Boudes.